Nobuyuki Tajima
Overview
Explore the profile of Nobuyuki Tajima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagao N, Tajima N, Kawai M, Niwa C, Kurosawa N, Matsuyama T, et al.
Bioresour Technol
. 2012 Jun;
118:210-8.
PMID: 22705526
Anaerobic digestion of food waste was conducted at high OLR from 3.7 to 12.9 kg-VS m(-3) day(-1) for 225 days. Periods without organic loading were arranged between the each loading...
2.
Yamaguchi T, Kakefuda R, Tanimoto A, Watanabe Y, Tajima N
Inflamm Res
. 2012 Jan;
61(5):445-54.
PMID: 22245957
Objective And Design: To examine the effects of a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2-inhibitor, JTP-74057, on inflammatory arthritis development, and compare its anti-arthritic effect with leflunomide. Materials: Human,...
3.
Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T
Int J Oncol
. 2011 Apr;
39(1):23-31.
PMID: 21523318
The MAPK pathway is one of the most important pathways for novel anticancer drug development. We performed high-throughput screening for compounds that induce expression of p15INK4b, and identified JTP-74057 (GSK1120212),...
4.
Tajima N, Takai M, Ishihara K
Anal Chem
. 2011 Feb;
83(6):1969-76.
PMID: 21338074
To investigate the effect of antibody orientation on its immunological activities, we developed a novel and versatile platform consisting of a well-defined phospholipid polymer surface on which staphylococcal protein A...
5.
Tajima N, Fukui K, Uesato N, Maruhashi J, Yoshida T, Watanabe Y, et al.
Cancer Sci
. 2009 Dec;
101(3):774-81.
PMID: 20028380
Proinflammatory cytokines and growth factors have been thought to play crucial roles in the pathology of acute myelogenous leukemia (AML) by supporting the proliferation and survival of AML cells in...
6.
Tajima N, Tezuka K, Tanimoto A, Miyai A, Tanimoto M, Maruhashi J, et al.
Exp Hematol
. 2008 Aug;
36(11):1514-23.
PMID: 18715691
Objective: Activation-inducible lymphocyte immunomediatory molecule (AILIM; also referred to as inducible costimulator [ICOS]) is the third molecule identified in the CD28 family participating in T-cell activation. AILIM/ICOS has been implicated...
7.
Tajima N, Tezuka K, Tanaka M, Tanimoto M, Miyai A, Takeshima H, et al.
Hum Immunol
. 2008 Jul;
69(7):399-408.
PMID: 18638655
Activation-inducible lymphocyte immunomediatory molecule (AILIM; also referred to as inducible costimulator, ICOS) is the third homolog of the "professional" costimulatory molecule, CD28. To date, the characteristics and role of AILIM/ICOS,...
8.
Yamaguchi T, Yoshida T, Kurachi R, Kakegawa J, Hori Y, Nanayama T, et al.
Cancer Sci
. 2007 Sep;
98(11):1809-16.
PMID: 17784872
The INK4 family members p16(INK4a) and p15(INK4b) negatively regulate cell cycle progression by inhibition of cyclin-dependent kinase (CDK) 4/6. Loss of p16(INK4a) functional activity is frequently observed in tumor cells,...
9.
Uesato N, Fukui K, Maruhashi J, Tojo A, Tajima N
Exp Hematol
. 2006 Sep;
34(10):1385-92.
PMID: 16982331
Objective: Accumulating findings suggest that in acute myeloid leukemia (AML) patients, proinflammatory cytokines and growth factors play important roles in the proliferation and survival of AML cells in an autocrine...